Rahul Banerjee, MD, FACP

What the Oncology Field Can Learn From The White Lotus Editor in Chief Dr. Rahul Banerjee's April Letter from the Editor explains what the oncology field can learn from "The White Lotus."

What can #TheWhiteLotus teach us about cancer care? 🏝️ Dr. Rahul Banerjee, explores “time toxicity” and why every patient’s journey is unique. How can we better tailor care? Read more: ow.ly/lqjr50VM5zO #Oncology #PatientCare

Thank you Yan!!

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evg

New study in Blood Advances led by Rahul Banerjee & Gurbakhash Kaur challenges the 8-week driving restriction for patients receiving CAR-T therapy for multiple myeloma (MM). Researchers analyzed 586 patients and found that only 1% experienced driving-relevant adverse events (drAEs) between Weeks 5-8

Rahul Banerjee, MD, (@rahulbanerjeemd.bsky.social) discussed approaches to dosing and tolerability when using talquetamab in patients with relapsed/refractory multiple myeloma. #mmsm | @uwmedicine.bsky.social @fredhutch.bsky.social

www.targetedonc.com/view/banerje...

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evg

@rahulbanerjeemd.bsky.social @fredhutch.bsky.social @mountsinainyc.bsky.social @mountsinai.bsky.social

ashpublications.org/bloodadvance...

Rahul Banerjee: Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma - OncoDaily Rahul Banerjee: Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma / cancer, Financial Toxicity of Drugs, OncoDaily, Oncology

Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma - Rahul Banerjee
@rahulbanerjeemd.bsky.social

oncodaily.com/drugs/financ...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MM #MultipleMyeloma #Myeloma #Lenalidomide

Rahul Banerjee: Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma - OncoDaily Rahul Banerjee: Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma / cancer, Cancer Therapy Advisor, MM, multiple myeloma,

Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma - Rahul Banerjee
@rahulbanerjeemd.bsky.social @cancertherapyadv.bsky.social

oncodaily.com/insight/rahu...

#Cancer #CancerResearch #HairLoss #Myeloma #BloodCancer #CancerTreatment #Oncology #OncoDaily

My takeaways from RedirecTT-1 (tal/tec dual bsAbs in myeloma #MMsm) for @fredhutch journal watch.

[Images but technically no memes in my talk 😉]

Efficacy & safety profiles are both striking! I can't help but wonder what earlier IVIG and bsAb de-escalation might have done.

At #ASH24, we caught up with Rakesh Popat to hear the interim results of the ProMMise trial evaluating belantamab + cyclophosphamide & dexamethasone in R/R #Myeloma.

Watch here:
👉https://buff.ly/3W3Cgy2

#MMSM #CTSM #TrialUpdate #MultipleMyeloma #HemeSky #HemeOnc
@ash-hematology.bsky.social

Episode 31 - Advanced Myeloma Nursing with A/Prof Tracy King — Bloody Minded Thankfully, it's time for an actual expert to join us again on Bloody Minded! We are thrilled to be sitting down and chatting with A/Prof. Tracy King , Myeloma CNC from RPA Hospital in Sydney, Co-Fou...

Very excited to have Prof Tracy King @mmkingt.bsky.social on for a look at the ins and outs of myeloma nursing! She makes a great friendalidomide to anyone navigating this area, wherever you get your podcasts #myeloma #hemesky #meded

www.bloodyminded.com.au/allepisodes/...

The PANGEA 2.0 model leverages trajectory data to improve the risk stratification of individuals with #SmolderingMyeloma.

Learn more in our recent interview with the lovely Irene Ghobrial:

👉https://buff.ly/49ZYSFl

#Myeloma #MMSM #ASH24 #Hematology #HemeSky #HemeOnc @ash-hematology.bsky.social

T cell malignancies after CAR T cell therapy in the DESCAR-T registry - Nature Medicine This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows th...

Happy to share our work published in Nature Medicine!

We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY

Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma @mayocliniccancer.bsky.social #mmsm #oncology
www.onclive.com/view/subcuta...

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis Key PointsDexamethasone dose reductions <40 to 60 mg weekly are common in multiple myeloma, even for patients enrolled on clinical trials.In our large a

Dexamethasone dose reductions during multiple myeloma treatment show no difference in survival outcomes, highlighting the need for further research.

by Banerjee R, Sexton R (...) Orlowski RZ et 11 al. in Blood #MedSky

📖 read the article:

Abstract Title: #3765 Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Abstract Title: #445 Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience.

Two cool #ASH24 abstracts on reducing logistical toxicity for patients:

1. A via @rahulbanerjeemd.bsky.social et al: multi-method real world data to show <1% new-onset CRS/ICANS weeks 5-8-- let people drive! Key for getting to follow up appts after returning home.

You are too kind, thank you!! #ASH24 looking forward to many more projects with both of your guidance!

Care partners favorite - the “Down with Dex” doctor! @rahulbanerjeemd.bsky.social @ctoddkennedy.bsky.social

Fred Hutch at #ASH24: Catch @rahulbanerjeemd.bsky.social present results of a phase 3 clinical trial of 500 patients demonstrating that 24-hour urine assessments do not add any value or improve prognosis. 👉 bit.ly/49jbaIo

Let’s throw out the jugs!
@rahulbanerjeemd.bsky.social presents “24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702” #ASH24

#ASH24 #leusm Heuser: Proposes a reasonable evolution for the meaning of the term MRD. @drchrishourigan.bsky.social @rahulbanerjeemd.bsky.social

Free multiple myeloma response criteria from the pee! Excellent #ASH24 presentation by @rahulbanerjeemd.bsky.social showing that removing 24-hr urine changes response for only 1.1% of 645 patients in the BMT CTN 0702 clinical trial.

Can 24h urine be eliminated as part of IMWG response criteria in myeloma? Secondary analysis of STaMINA by @rahulbanerjeemd.bsky.social at #ASH24 showed that eliminating 24h urine resulted in changed response in 1% with no impact on PFS prediction at any response depth. #hemesky #oncsky #mmsm

What a blast #ASH24 has been!🎥🗞️🩸🇺🇸

Thank you to everyone who has been stopping by our booth 🧡

& BIG thank you to everyone who spoke with us🎙️

Stay tuned as we continue to share our exclusive coverage 👀 👉 vjhemonc.com/event/ash-2024

@ash-hematology.bsky.social @rahulbanerjeemd.bsky.social

#HemOnc

Also out in @BloodAdvances during #ASH24 by rising 🌟 @nadineabdal and @MayoMyeloma!

PROs strongly correlate with OS in #MMsm. In MVA, fatigue as prognostic for OS as FISH and ASCT 😳

Some confounders (anemia, frailty) but worth studying interventions!

ashpublications.org/bloodadvance...

Out in @bloodjournal during #ASH24 - cool work by @freemanlciaraMD @DrFredLocke et al looking at #MMsm CAR-T in myeloma:

MTV (by PET-CT), sBCMA, BMPC don't always correlate. Some MTV-high but sBCMA-low pts exist - may not respond durably to BCMA CAR-T.

ashpublications.org/blood/articl...

Probably to add word count since there unfortunately wasn’t much else to say back then!

It's really incredible how far things have come.

When I started they all started “We have done thousands of trials in the last 3 decades and none have significant improved survival”, now if we could only stop saying it is incurable. True for the majority but there is a small group that should be acknowledged or at least debated even in IMID/PI era